These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37596504)

  • 21. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
    Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis.
    Situ M; Schwarz UI; Zou G; McArthur E; Kim RB; Garg AX; Sarma S
    Eur J Health Econ; 2024 Apr; 25(3):397-409. PubMed ID: 37195343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.
    Kamel H; Easton JD; Johnston SC; Kim AS
    Neurology; 2012 Oct; 79(14):1428-34. PubMed ID: 22993279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
    Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
    JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
    Canestaro WJ; Patrick AR; Avorn J; Ito K; Matlin OS; Brennan TA; Shrank WH; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):724-31. PubMed ID: 24221832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
    Wang Y; Xie F; Kong MC; Lee LH; Ng HJ; Ko Y
    Cardiovasc Drugs Ther; 2014 Dec; 28(6):575-85. PubMed ID: 25319314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
    Dorian P; Kongnakorn T; Phatak H; Rublee DA; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Lip GY
    Eur Heart J; 2014 Jul; 35(28):1897-906. PubMed ID: 24513791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function.
    Salcedo J; Hay JW; Lam J
    Int J Cardiol; 2019 May; 282():53-58. PubMed ID: 30518479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
    Altawalbeh SM; Alshogran OY; Smith KJ
    Value Health; 2018 Dec; 21(12):1365-1372. PubMed ID: 30502779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
    Wisløff T; Hagen G; Klemp M
    Pharmacoeconomics; 2014 Jun; 32(6):601-12. PubMed ID: 24715603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
    Gulati S; Eckman MH
    Ann Intern Med; 2023 Jan; 176(1):1-9. PubMed ID: 36571839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country.
    Syeed MS; Nonthasawadsri T; Nelson RE; Chaiyakunapruk N; Nathisuwan S
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):173-183. PubMed ID: 36735211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation in Hong Kong.
    Peng K; Li Y; Chan EW; Wong ICK; Li X
    Value Health Reg Issues; 2023 Jul; 36():51-57. PubMed ID: 37030031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China.
    Liu L; Hong D; Ma K; Lu X
    J Clin Pharm Ther; 2021 Jun; 46(3):658-668. PubMed ID: 33226144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.